- UPDATE: The Novo Nordisk Ruling That Creates a Bill of Rights for Office Sex Pests at Drug Companies
In the case, BMS scientist Diana Hiraldo complained to her supervisor, Luis Collazo, that one of her colleagues was calling her frequently and leering at her while on the job. Collazo organized a meeting between her and BMS HR specialist Edgardo GarcÃa, at which Hiraldo explained her problem and Garcia told her about the grievance process.
BMS then laid off Collazo in what it claimed was a "reorganization." The court noted that in that reorg, the only person laid off was Collazo and that BMS's own HR director had not seen any documents discussing the reorganization.
Collazo sued, claiming that his firing was retaliation for engaging in a protected activity -- protesting sexual harassment at work. The judges noted:
Bristol-Myers argues that Collazo did not "oppose" any discriminatory conduct because he "did not utter words" during the meetings with GarcÃa but instead "simply listened to Hiraldo."That's breathtaking. BMS is trying to justify firing someone for doing the right thing: introducing an employee to the very HR people who are supposed to prevent harassment in the workplace. By not opening his mouth he wasn't opposing the harassment, and therefore could not have been retaliated against by the company, BMS argued. (BMS ignored the fact that immediately after the meeting Collazo said to Garcia that this was a "serious case, a serious case where this girl alleges that she is being sexually harassed by this guy," the ruling states.)
HR executives might also want to note that, once again, it's not the harassment itself that generated the lawsuit liability, it was the retaliation against the employee who complained about it.
- Wyeth Case: It's Not Race Discrimination That Counts, It's the Retaliation
- HR Hell at Novartis: Alleged Rape Victim Threatened With "Disciplinary Action"
- Senate Probe Might Want to Ask Why Drug Companies Invite Lawsuits By Punishing Whistleblowers
- Terminating the Pregnant Employee: Novartis Emails Lay Out the Appalling Tale